Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors

By afschroeder • August 26, 2025

Anderson KG, Ribas A. Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors. J Immunother Cancer. 2025 Aug 25;13(8):e013061. doi: 10.1136/jitc-2025-013061. PMID: 40854816.

Tags: Biomarker, Circulating tumor DNA - ctDNA, colorectal cancer, Hematology/Oncology, immune checkpoint inhibitor, Mismatch repair - MMR, Publications

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]

Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies

Ramesh K, Hui G, Shodiya M, Palaskas NJ. Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies. Cureus. 2026 Jul 29;18(7):e113621. doi: 10.7759/cureus.113621.[...]

Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report

Rashba GB, Kaplan L, Bolos D, Baltayan A, Backer S. Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report. Cureus.[...]